Computer analysis of prostate biopsy samples to predict cancer spread
Tests a computer model that predicts cancer spread from prostate biopsies.
Plain-language title generated from the registry record
Registry title: AI-based Prediction of Prostate Cancer Metastasis Using Biopsy Pathology
Key facts
- Where
- Changsha, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for men aged 18 to 90 with prostate cancer found on biopsy, who then had prostate surgery with lymph node removal, to build and test an AI prediction model.
- Age
- 18 to 90 years
- Sex
- Men only
- Disease stage
- Prostate cancer confirmed on biopsy. Lymph node status known from surgery with pelvic lymph node removal. Scans (PSMA PET/CT, MRI or bone scan) able to show spread to lymph nodes or other organs.
- Earlier treatment
- Must have had prostate surgery (radical prostatectomy) with pelvic lymph node removal. A stored prostate biopsy sample must be available.
Main reasons for not taking part
- History of another cancer
- Serious heart, lung, liver or kidney problems
- Expected survival of less than 1 year
- Biopsy slide scan of poor quality
- Prostate cancer found on a sample from transurethral resection
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07660276, who can take part
Where in China
- Xiangya Hospital Central South UniversityChangsha, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xiangya Hospital of Central South University
- Trial code
- NCT07660276
- Record updated
- 22 June 2026
- Original description
This observational study aims to develop and validate an artificial intelligence-based model using prostate cancer biopsy pathology to predict lymph node metastasis and distant metastasis in patients with prostate cancer. The main questions it aims to answer are:Read full original descriptionShow less
Development and Validation of an AI-Based Metastasis Prediction Model Using Prostate Cancer Biopsy Pathology
This observational study aims to develop and validate an artificial intelligence-based model using prostate cancer biopsy pathology to predict lymph node metastasis and distant metastasis in patients with prostate cancer. The main questions it aims to answer are:
Can artificial intelligence-assisted analysis of prostate cancer biopsy pathology accurately predict lymph node metastasis? Can the model accurately predict distant metastasis and assess metastatic risk in patients with prostate cancer?
Researchers aim to evaluate whether the model can provide additional information for clinical decision-making and surgical planning.
Participants will:
Provide prostate biopsy pathology specimens and related clinical information; Undergo assessment of lymph node and distant metastatic status based on clinical and imaging data; Be included in the development and validation of the artificial intelligence prediction model.
Inclusion: Male patients aged between 18 and 90 years; Patients who underwent prostate biopsy due to elevated prostate-specific antigen (PSA), abnormal digital rectal examination (DRE), or abnormal imaging findings, were pathologically diagnosed with prostate cancer, and had available prostate biopsy pathology specimens; Patients who underwent radical prostatectomy with extended pelvic lymph node dissection (ePLND) or pelvic lymph node dissection (PLND), with definitive pathological information regarding lymph node metastasis; Patients who underwent PSMA PET/CT, MRI, bone scintigraphy, or prostate MRI capable of identifying regional lymph node metastasis or distant metastasis; Adequate cardiac, pulmonary, hepatic, and renal function; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Expected survival time greater than 1 year; Written informed consent signed by the patient or legally authorized representative.
Exclusion: History of other malignancies; Severe dysfunction of major organs, including cardiac, pulmonary, hepatic, or renal insufficiency, or an expected survival time of less than 1 year; Prostate biopsy pathology specimens with inadequate whole-slide image scanning quality or failure of quality control assessment; Patients with prostate cancer diagnosed from transurethral resection specimens.